Thursday, December 3, 2015

True North Therapeutics Gets $40M

South San Francisco-based biotherapeutics developer True North Therapeutics announced this morning that it has raised $40M in a Series C funding. The funding came from Newaf Venture Partners, along with Perceptive Advisors, Cowen Private Investments, plus Kleiner Perkins Caufield & Byers, MPM Capital, OrbiMed, SR One, and Baxalta Ventures. Issac Manke of New Leaf joins the company's board with the funding. True Nroth is focused on treatments for Cold Agglutinin Disease (CAD).